



شبكة المعلومات الجامعية

بسم الله الرحمن الرحيم



شبكة المعلومات الجامعية
@ ASUNET



شبكة المعلومات الجامعية التوثيق الالكتروني والميكرو فيلم



شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الالكتروني والميكرو فيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأفلام قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأفلام بعيدا عن الغبار

في درجة حرارة من ١٥-٢٥ مئوية ورطوبة نسبية من ٢٠-٤٠%

To be Kept away from Dust in Dry Cool place of
15-25- c and relative humidity 20-40%

بعض الوثائق الأصلية تالفة

بالرسالة صفحات لم ترد بالاصل



***STUDIES ON ORAL DELIVERY OF CERTAIN
PEPTIDE DERIVATIVES***

A THESIS

Presented by

Gihan Nabil Hassan Fetih

**SUBMITTED FOR THE DEGREE OF DOCTOR OF
PHILOSOPHY IN PHARMACEUTICAL SCIENCES
(PHARMACEUTICS)**

Supervised By

Prof. Dr. *Mohamed Ali Attia*

Professor of Pharmaceutics

Faculty of Pharmacy,

Assiut University

Prof. Dr. *Fawzia Sayed Ahmed Habib*

Professor of Pharmaceutics

Faculty of Pharmacy,

Assiut University

Prof. Dr. *Akira Yamamoto*

Professor of Pharmaceutics

Kyoto Pharmaceutical University,

Japan

Department of Pharmaceutics

Faculty of Pharmacy - Assiut University

2005


Approval Sheet


Approved by :











«وَقُلْ رَبِّ زِدْنِي عِلْمًا»



Acknowledgement

ACKNOWLEDGEMENT

All thanks to ALLAH, most gracious and most merciful, by the help of whom this work was done.


I would like to express my sincerest gratitude to Professor Dr. **Mohamed Ali Attia**, Professor of Pharmaceutics, Dept. of Pharmaceutics, Faculty of Pharmacy, Assiut University, for suggesting the subject of the thesis and being behind every step in the work with all the support and advise it needed.

I am deeply grateful to Professor Dr. **Fawzia Sayed Ahmed Habib**, Professor of Pharmaceutics, Dept. of Pharmaceutics, Faculty of Pharmacy, Assiut University, for the continuous guidance and encouragement during this work.

My deepest thanks and great appreciation to Professor Dr. **Akira Yamamoto**, Professor of Pharmaceutics, Dept. of Biopharmaceutics, Kyoto Pharmaceutical University, for his valuable supervision, useful advice and great support during my stay in Japan.

I am deeply grateful to Professor Dr. **Mohamed Mounir Shahwan**, Professor of Endocrinology, Dept. of Internal Medicine, Faculty of Medicine, Assiut University and Dr. **Mohamed El-Yamani**, Lecturer of Internal Medicine, Dept. of Internal Medicine, Faculty of Medicine, Assiut University, for their help in accomplishing the clinical part of the thesis.

My appreciation to all my colleagues and staff members of the Pharmaceutics Dept., Faculty of Pharmacy, Assiut University, and the Dept. of Biopharmaceutics, Kyoto Pharmaceutical University, who in one way or another helped me throughout this work.



Abbreviations

ABBREVIATIONS

AAC: Area above the curve.

ALP: Alkyl phosphatase.

AUC: Area under the curve.

CF: 5-(6)-carboxyfluorescein.

CT: Calcitonin.

C-PTIO: 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazole-1-oxyl
3-oxide.

E.Ratio: Enhancement ratio.

GOD: Glucose oxidase.

HPMCP: Hydroxypropyl methylcellulose phthalate.

IU: International unit.

LDH: Lactate dehydrogenase.

LM: n-dodecyl- β -D-maltoside.

NAD: Nicotinamide dinucleotide.

Na Cap.: Sodium caprate.

Na GC: Sodium glycocholate.

Na Sal.: Sodium salicylate.

NOC5: 3-(2-hydroxy-1-(methylethyl)-2-nitrosohydrazino)-1-
propanamine.

NOC12: N-ethyl-2-(1-ethyl-hydroxy-2-nitrosohydrazino)-
ethanamine.

OCPC: o-Cresophthalein complexon.


PA: Pharmacological availability.

PBS: Phosphate buffered saline.

P-gp: P-glycoprotein.

POD: Peroxidase.

SNAP: S-nitroso-N-acetyl-DL-penicillamine.



Contents

CONTENTS

	Page
Abstract	I
1. Introduction	1
2. Scope of Work	41
3. Experimental	44
3.1. Materials	44
3.2. Equipment	45
3.3. Procedures	45
3.3.1. <i>In-Vitro</i> Permeability Experiments	45
3.3.1.1. Drug Solution Preparation	45
3.3.1.2. Experimental Procedure	46
3.3.2. Absorption Experiments	48
3.3.2.1. Drug Solution Preparation	48
3.3.2.2. Experimental Procedure	48
3.3.3. Preparation and Administration of Capsules (<i>In-Vivo</i> Study)	50
3.3.4. Study of the Mechanism of Action of Nitric Oxide Donors	53
3.3.4.1. Effect of Carboxy-PTIO on the Absorption Enhancing Effect of Nitric Oxide Donors	53
3.3.4.2. Stability of Insulin in the Gastrointestinal Homogenates	53
3.3.4.2.1. Preparation of Intestinal Mucosal Tissue Homogenates	54
3.3.4.2.2. Experimental Details	55
3.3.4.3. Effect of Nitric Oxide Donors on the Function of Intestinal P-glycoprotein	55
3.3.4.3.1. Solution Preparation	56

	Page
3.3.4.3.2. Experimental Procedure.....	56
3.3.5. Toxicity Studies.....	58
3.3.6. Analytical Methods.....	59
3.3.6.1. Spectrofluorometric Analysis.....	59
3.3.6.2. HPLC Condition.....	60
3.3.6.3. Glucose Assay.....	60
3.3.6.4. Calcium Assay.....	61
3.3.6.5. Determination of Lactate Dehydrogenase.....	61
3.3.6.6. Determination of Alkyl Phosphatase.....	62
3.3.6.7. Determination of Protein (The Lowry Assay).....	63
3.3.7. Clinical Study.....	63
3.3.7.1. Preparation of Capsules.....	64
3.3.7.2. Study Design.....	65
3.3.8. Statistics.....	67
4. Results and Discussion.....	68
4.1. <i>In-Vitro</i> Permeability Studies.....	68
4.2. Absorption Experiments.....	91
4.3. Administration of Capsules (<i>in-Vivo</i> Study).....	124
4.4. Study of the Mechanism of Action of Nitric Oxide Donors..	141
4.4.1. Effect of Carboxy-PTIO on the Absorption Enhancing Enhancing Effect of Nitric Oxide Donors.....	141
4.4.2. Stability of Insulin in the Gastrointestinal Homogenates	147
4.4.3. Effect of Nitric Oxide Donors on the Function of Intestinal P-glycoprotein	150
4.5. Toxicity Studies.....	168
4.6. Clinical Study.....	172
5. Conclusion.....	184
References	187
Arabic Summary	